Spots Global Cancer Trial Database for locally advanced
Every month we try and update this database with for locally advanced cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | NCT03761901 | Carcinoma, Non-... | 1L treatment 2L Treatment 3L treatment | 18 Years - | AstraZeneca | |
| CRLX101 Plus Bevacizumab in Advanced RCC | NCT01625936 | Renal Cell Carc... | CRLX101 (Cerule... Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| NSABP Biospecimen Discovery Project | NCT01850628 | Breast Cancer | Paclitaxel trastuzumab pertuzumab | 18 Years - | NSABP Foundation Inc | |
| Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer | NCT01396668 | Pancreatic Canc... | gemcitabine, ci... | 18 Years - 75 Years | Seoul National University Hospital | |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | NCT02917993 | Lung Cancer | Itacitinib Osimertinib | 18 Years - | Incyte Corporation | |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | NCT03027128 | Solid Tumor | haNK™ for Infus... | 18 Years - | ImmunityBio, Inc. | |
| Exclusion of Non-involved Uterus From the Target Volume in Locally Advanced Cervical Cancer | NCT03542942 | Uterine Cervica... | treatment with ... | 18 Years - | University Hospital, Ghent | |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | NCT01318642 | Adenocarcinoma ... Locally Advance... Unresectable | Gemcitabine AMG 479 Placebo | 18 Years - | Amgen | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | NCT01347645 | Colon Cancer Rectal Cancer | FOLFIRI E7820 | 18 Years - | Eisai Inc. | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Cetuximab + Gemox in Biliary Tract Cancer | NCT01216345 | Unresectable Locally Advance... Metastatic | Cetuximab + Gem... | 18 Years - | Association of Research on the Biology of Liver Tumors | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | NCT03916510 | Locally Advance... | Enadenotucirev Capecitabine Radiotherapy | 18 Years - | University of Oxford | |
| Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer | NCT01821729 | Pancreatic Canc... | FOLFIRINOX Losartan Proton Beam Rad... | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma | NCT01286766 | Gastric Cancer | DCS (docetaxel ... DCF (docetaxel ... | 18 Years - 70 Years | Yonsei University | |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | NCT05766800 | Locally Advance... Non-small Cell ... | Serplulimab Carboplatin Pemetrexed Nab-paclitaxel Liposomal pacli... Surgery Radiotherapy | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC | NCT02799862 | Carcinoma, Non-... | Nab-Paclitaxel Carboplatin | 18 Years - 99 Years | iOMEDICO AG | |
| Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | NCT04612894 | Thyroid Cancer | Camrelizumab an... surgery core needle bio... | 14 Years - | Fudan University | |
| A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments | NCT01529112 | Non-Small Cell ... | Lenvatinib Lenvatinib matc... BSC | 18 Years - | Eisai Inc. | |
| Docetaxel and Capecitabine in Advanced Gastric Cancer | NCT00142038 | Stomach Neoplas... Neoplasm Metast... | Docetaxel Capecitabine | 18 Years - 75 Years | Charite University, Berlin, Germany | |
| Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer | NCT01787006 | Esophageal Canc... | Cetuximab Cisplatin, 5-FU Radiotherapy | 18 Years - | University Hospital Schleswig-Holstein | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine | NCT01020006 | Pancreatic Canc... Ductal Adrenoca... Exocrine Pancre... | PCI-27483 Gemcitabine | 18 Years - | Pharmacyclics LLC. | |
| Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer | NCT04112836 | Pancreatic Canc... Exocrine Pancre... Metastatic Panc... Chemotherapy Malnutrition Locally Advance... | 18 Years - | Moscow Clinical Scientific Center | ||
| ECI301 and Radiation for Advanced or Metastatic Cancer | NCT01441115 | Cancer Neoplasm Metast... Radiation Oncol... Neoplasm Metastasis | Radiation Thera... ECI301 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer | NCT05576480 | Rectal Cancer Locally Advance... | Short-course ra... Penpulimab CAPEOX TME surgery | 18 Years - 75 Years | Ruijin Hospital | |
| New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma | NCT03558035 | Hypopharyngeal ... | Induction CT+ C... Concurrent CRT ... | 18 Years - 70 Years | ChineseAMS | |
| Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy | NCT00343720 | Non-Small Cell ... | VELCADE Alimta | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | NCT01700049 | Basal Cell Carc... | vismodegib (150... | 18 Years - | Mayo Clinic | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas | NCT00377936 | Adenocarcinoma Metastasis Pancreas Neopla... | Gemcitabine alo... EndoTAG-1 and G... EndoTAG-1 and G... EndoTAG-1 and G... | 18 Years - | MediGene | |
| A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane | NCT03003078 | Unresectable Lo... | OncoSil™ | 18 Years - | OncoSil Medical Limited | |
| A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | NCT05386888 | NSCLC, Stage II... | GFH018 Toripalimab Paclitaxel Carboplatin Cisplatin Pemetrexed Thoracic Radiat... GFH018 | 18 Years - | Genfleet Therapeutics (Shanghai) Inc. | |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | NCT02777385 | Head and Neck S... | Pembrolizumab Cisplatin IMRT | 18 Years - | University of Pittsburgh | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies | NCT04729205 | Cancer Gastro-Intestin... | Promitil | 18 Years - | Lipomedix Pharmaceuticals Inc. | |
| Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer | NCT00347438 | Breast Cancer | Capecitabine | 18 Years - | University of Chicago | |
| Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer | NCT00116142 | Prostate Cancer | Docetaxel Androgen Hormon... Androgen Suppre... | 30 Years - | Dana-Farber Cancer Institute | |
| Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca | NCT00756132 | Locally Advance... Breast Cancer | 18 Years - 65 Years | University Health Network, Toronto | ||
| Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | NCT01700049 | Basal Cell Carc... | vismodegib (150... | 18 Years - | Mayo Clinic | |
| A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03646071 | Locally Advance... Metastatic Soli... | RX108 | 18 Years - | NeuPharma, Inc. | |
| Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) | NCT01126138 | Carcinoma, Inva... | Vinorelbine plu... Docetaxel plus ... | 18 Years - | ChineseAMS | |
| Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | NCT02308072 | Head and Neck C... | Olaparib Cisplatin IMRT | 18 Years - | University College, London | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Docetaxel and Capecitabine in Advanced Gastric Cancer | NCT00142038 | Stomach Neoplas... Neoplasm Metast... | Docetaxel Capecitabine | 18 Years - 75 Years | Charite University, Berlin, Germany | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Abiraterone Acetate in Molecular Apocrine Breast Cancer | NCT01842321 | Breast Cancer | Abiraterone Ace... | 18 Years - | UNICANCER | |
| Docetaxel and Capecitabine in Advanced Gastric Cancer | NCT00142038 | Stomach Neoplas... Neoplasm Metast... | Docetaxel Capecitabine | 18 Years - 75 Years | Charite University, Berlin, Germany | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | NCT03761901 | Carcinoma, Non-... | 1L treatment 2L Treatment 3L treatment | 18 Years - | AstraZeneca | |
| Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer | NCT00350142 | Pancreatic Canc... | Stereotactic Bo... Gemcitabine 4D pancreatic p... FDG PET scan | 18 Years - 90 Years | Stanford University | |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux | NCT00609284 | HNSCC | cetuximab Carboplatin, 5F... Radiotherapy | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Adaptative Radiotherapy for Locally Advanced Cervical Cancer | NCT02937948 | Uterine Cervica... | Adaptative trea... External radiot... | 18 Years - | Center Eugene Marquis | |
| Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | NCT02762006 | Renal Cell Carc... Kidney Cancer | Durvalumab Tremelimumab | 18 Years - | Case Comprehensive Cancer Center | |
| CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT | NCT01760811 | Squamous Cell C... | Erbitux,merck s... | 18 Years - 80 Years | Rabin Medical Center | |
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | NCT04163900 | Biliary Tract C... | NUC-1031 Gemcitabine Cisplatin | 18 Years - | NuCana plc | |
| Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer | NCT03691441 | Oropharyngeal C... | Resection Radiotherapy Chemotherapy Salvage neck di... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | NCT00434031 | Breast Cancer | docetaxel cyclophosphamid... trastuzumab liposomal doxor... | 18 Years - 65 Years | National Cancer Institute, Naples | |
| Clinical Study of SM3321 With Solid Tumors | NCT06087770 | Locally Advance... | SM3321 | 18 Years - | Beijing StarMab Biomed Technology Ltd | |
| Clinical Study of SM3321 With Solid Tumors | NCT06087770 | Locally Advance... | SM3321 | 18 Years - | Beijing StarMab Biomed Technology Ltd | |
| Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00813072 | Stomach Neoplas... Esophageal Neop... | PEP02 irinotecan docetaxel | 18 Years - | PharmaEngine | |
| Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC | NCT04153734 | Locally Advance... | Pembrolizumab Cis Platinum Carboplatin Pemetrexed nab paclitaxel | - | Kobe Minimally Invasive Cancer Center | |
| Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | NCT01304160 | Pancreatic Canc... Unresectable Pa... | stereotactic bo... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Adaptative Radiotherapy for Locally Advanced Cervical Cancer | NCT02937948 | Uterine Cervica... | Adaptative trea... External radiot... | 18 Years - | Center Eugene Marquis | |
| Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment | NCT02017496 | Breast Cancer | 18 Years - | Oslo University Hospital | ||
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| BiPAP-Vapotherm RCT | NCT01518140 | Advanced Cancer... | Oxygen Delivery... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 | Head and Neck C... | Cetuximab Nab-paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| ER Reactivation Therapy for Breast Cancer | NCT02188745 | Metastatic Brea... | 17B-estradiol Letrozole Anastrozole Exemestane | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Minocycline Study in Pancreatic Cancer Patients | NCT01693523 | Pancreatic Canc... | Minocycline Placebo Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | NCT01797900 | Nasopharyngeal ... | Cisplatin Paclitaxel IMRT | 18 Years - 70 Years | ChineseAMS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
